| INTRODUC TI ON
Postpartum hemorrhage (PPH) is a serious obstetric complication and a major contributor to maternal morbidity and mortality worldwide. 1 Its incidence seems to be increasing in high-income countries accompanied by increasing rates of severe adverse outcomes. 2 In obstetrics, massive transfusion (defined as 8 or more units of packed red blood cells transfused) after birth is associated with high rates of morbidity and hysterectomy. per 100 000 births). [3] [4] [5] A nationwide study based on the national perinatal database in the Netherlands showed an increased incidence of PPH (defined as ≥ 1000 mL blood loss following the first 24 h after birth) between 2004 and 2013 (from 4.1% to 6.4% of women giving birth), but a decreased incidence of any number of obstetric-related transfusion of packed red blood cells (from 23% to 3.9% of all women with PPH). 6 It is unknown whether the number of women receiving massive transfusion due to PPH followed this same decreasing pattern. Assessing such a pattern and discerning possible differences over time in incidence, causes, management and outcome of PPH leading to massive transfusion could help to evaluate maternity care. Moreover, identifying antepartum risk factors may also raise awareness for women at high risk of receiving massive transfusion after birth.
The aim of this study was to describe incidence, causes, man- 
| MATERIAL AND ME THODS

| Study design
We performed a secondary analysis of women who received massive 
| Population
For the present analysis, women were selected from the 
| Statistical analyses
All statistical analyses were performed with IBM SPSS Statistics To estimate a population-based incidence of massive transfusion due to PPH, the number of births in the TeMpOH-1 study was multiplied by 100/71 to represent all births, including those under guidance of primary care.
| Ethical approval
The TeMpOH-1 study was approved by the ethics committee of the Leiden University Medical Center on 31 January 2013 (P12.273)
and by the institutional review board of each participating hospital. The study was registered in the Netherlands Trial Register (NTR4079). Need to obtain informed consent was waived by the ethics committee.
| RE SULTS
The 
| Characteristics of women and bleeding
Women who received massive transfusion due to PPH had a median (IQR) age of 32 years (29-37 years), BMI of 23 kg/m 2 (21-26 kg/ m 2 ) and a gestational age of 39 weeks (37-40 weeks). The characteristics of women, pregnancy and birth are presented in Table 1 and juxtaposed to the characteristics of women who experienced The median (IQR) estimated blood loss was 6000 mL (4500-8000 mL). (8) 16 (9) Table S1 ). Uterine atony also remained a leading cause when causes were grouped by the total units of packed red blood cells transfused:
| Risk factors and causes of hemorrhage
"moderate" (8-12 units, n = 113), "high" (13-20 units, n = 49) and "immense" (≥ 20 units, n = 14). Table 2 . between 2011 and 2012 (82% vs 70%), and sulprostone became the most frequent uterotonic drug administered during PPH leading to massive transfusion. 3 Misoprostol (34% vs 11%) and tranexamic acid (74% vs 22%) were seemingly administered more often as well, while it appears that ergometrine (10% vs 18%) and (non-prophylactic) oxytocin (64% vs 87%) were used less frequently over time. 
| Management of PPH
| Adverse maternal outcome
Of all women, 146 (83%) were admitted to an intensive care unit and 53 (30%) underwent hysterectomy as a last resort to stop bleeding.
Four women died (three due to exsanguination caused by uterine atony and one due to liver capsule rupture accompanied by uterine atony), of whom two died after hysterectomy. Case fatality rate of PPH with massive transfusion was one in 44 women (2.27%) and case fatality rate of women who underwent peripartum hysterectomy due to major PPH was two in 53 women (3.77%).
| D ISCUSS I ON
The incidence of massive transfusion due to PPH decreased in the it must be noted that these numbers can be influenced by clinical decision making. There is still no definite consensus in the literature as to which definition of massive transfusion should be applied. [12] [13] [14] Furthermore, number of births used as denominator for calculation of incidence of massive transfusion due to PPH was estimated by multiplying the number of hospital births in the TeMpOH-1 study by the proportion of births under guidance of primary care. However, since coverage of the PRN registry was about 99% of all births in the Netherlands and all women with hemorrhage receiving massive transfusion will eventually have been referred to a maternity unit, we believe that this estimate of incidence is reliable.
8
The decreased incidence of PPH leading to massive transfusion along with an observed increase in median blood loss reflects the more restrictive blood transfusion policy in the Netherlands over time. 6 This gradual change followed, among other things, after the introduction of the "4-5-6 rule" (depending on the presence of comorbidity, the threshold for transfusion of packed cells varies be- 3 This is known to be associated with increased risks of placenta previa, abnormally invasive placenta and uterine rupture during subsequent pregnancies. [17] [18] [19] Furthermore, studies showed that the risk of peripartum hysterectomy increased with the number of previous cesarean births and in the presence of an abnormally invasive placenta. [20] [21] [22] Other countries have reported increasing previous cesarean birth rates with an increasing trend in the incidence of placenta previa, abnormally invasive placenta and uterine rupture, which could suggest that more countries experience the high burden of hysterectomy due to PPH with massive transfusion. [23] [24] [25] Nevertheless, the hysterectomy rate in the the Netherlands remained substantially lower than in the UK, where the overall rate was 45%. 4 This difference could be explained by the lower rates of women with previous cesarean births in the Netherlands (26% vs 40% in the UK) and higher rates of embolization (48% vs 16% in the UK), which may avert hysterectomy in most cases. 4 The na- Gynaecologists specifically recommends to "resort to hysterectomy sooner rather than later" without explicitly mentioning the option of trying embolization first. 26, 27 This difference could lead to a more restrictive policy of peripartum hysterectomy in the Netherlands.
Furthermore, the incidence of PPH also depends on prevalence of risk factors in the population. Our findings confirm previous observations that increased maternal age (≥ 35 years), previous cesarean birth, multiple pregnancy, pre-eclampsia, labor induction, and instrumental or cesarean birth are associated with major PPH. 5, 11, 28, 29 These antepartum risk factors were only present in a certain number of women enduring major PPH. Considering that uterine atony remained the leading cause of PPH that required massive transfusion,
demonstrates that all obstetric caregivers should acknowledge the possible severity of uterine atony despite the absence of risk factors. In this respect, the substantial decrease of oxytocin use among women with PPH with massive transfusion due to uterine atony is striking, considering that the Dutch national guideline specifically recommends oxytocin as the uterotonic agent of first choice. 26 Although our findings rely on the accuracy of data entered into the TeMpOH-1 database, such a decrease is worrying and should be reported to all obstetric caregivers by emphasizing the importance of oxytocin in the Dutch national guideline on the management of PPH, which may reduce the need to resort to massive transfusion after childbirth.
Despite all changes over time, the maternal mortality ratio in women with PPH leading to massive transfusion in the Netherlands 
| CON CLUS ION
Incidence of PPH leading to massive transfusion decreased in the Netherlands, but continues to be an important cause of maternal morbidity and mortality. Improved continuous registration of major obstetric hemorrhage with confidential enquiries to identify substandard factors could lead towards better maternal care and may prevent morbidity and mortality from major PPH in the Netherlands.
International comparison of our findings could provide high-quality evidence for the best management practices of major PPH.
